You’re probably familiar with retail-ready packaging if you’re a manufacturer of retail products supplied to big box stores such as Kroger or Walmart, but are you using it? Because retailers prefer this secondary packaging, it’s in most manufacturers’ best interest to consider it, because it eliminates some of the headaches and costs for retailers. For example, when secondary packaging, such …
Pfizer Considers Sale Or Spin-Off Of Consumer Healthcare Business
Recently it was announced that, as health-conscious consumers and an aging population control increasing demand for self-medication, Pfizer is considering the sale or spin-off of the company’s consumer healthcare business, to the tune of $15 billion. In recent years, deal-making has become more pronounced as consumers’ desire for self-medication increases, whether in lip balms, headache medications, vitamins, or other OTC …
Pharma Marking – Ocaliva Incorrect Dosage Warning Issued By The FDA
Ocaliva (obeticholic acid) is a drug manufactured by Intercept Pharmaceuticals for treatment of PBC or primary biliary cholangitis, a rare and chronic disease of the liver that damages the organ as a result of the bile build-up that occurs when the bile ducts become damaged, inflamed, or are destroyed. Now, the FDA has issued a warning regarding excessive dosing of …
Trump Signs FDARA Into Law – Impact To Medical Products And Patients
On Friday August 18, President Trump signed FDARA (FDA Reauthorization Act 2017) into law. H.R. 2430 was passed by the House of Representatives on July 12, and the Senate passed the bill on August 3. This bipartisan legislation essentially reauthorizes the MDUFA (Medical Device User Fee Amendments), PDUFA (Prescription Drug User Fee Act), and other user fees that make it …
Pharma Coding – Bristol-Myers Squibb Acquires IFM Therapeutics
Recent news reports reveal that BMS and IFM Therapeutics have signed an agreement in which Bristol-Myers Squibb will acquire full rights to IFM’s NLRP3 and STING agonist programs in an effort to target innate immunity pathways that could potentially assist the body’s natural defenses in recognizing tumors and attacking them, expanding and complementing Bristol-Myers Squibb’s immuno-oncology portfolio. Reports claim BMS …